Delving into the Latest Updates on CV-0801(GlaxoSmithKline) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, mRNA vaccine

Synonyms

CV-0801

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

CureVac NV

GSK Plc

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine.
The purpose of Part B of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccine under three different storage conditions.

Start Date01 Aug 2023

Sponsor / Collaborator

GSK Plc

[+1]

100 Clinical Results associated with CV-0801(GlaxoSmithKline)

Login to view more data

100 Translational Medicine associated with CV-0801(GlaxoSmithKline)

Login to view more data

100 Patents (Medical) associated with CV-0801(GlaxoSmithKline)

Login to view more data

100 Deals associated with CV-0801(GlaxoSmithKline)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	United States	CureVac NV	01 Aug 2023
COVID-19	Phase 2	United States	GSK Plc	01 Aug 2023
COVID-19	Phase 2	Australia	CureVac NV	01 Aug 2023
COVID-19	Phase 2	Australia	GSK Plc	01 Aug 2023